- AstraZeneca (NYSE:AZN) last month informally got in touch with Gilead (NASDAQ:GILD) about a possible merger, according to the report. Terms weren't discussed, but Gilead has since reached out to advisers. Formal talks between the two, however, aren't yet underway.
- AstraZeneca has a market cap of $140B; Gilead of $96B. Should a deal happen, it would easily surpass last year's Bristol-Myers/Celgene $74B tie-up as the largest-ever healthcare merger.